Document is current

Article History

Received: 19 July 2021

Accepted: 9 October 2021

First Online: 3 November 2021

Declarations

:

: This study was approved by the Vanderbilt University Medical Center IRB (160979) and the Duke University Health System IRB (Pro00101984). Consent for participation in this retrospective analysis was waived given lack of identifiable patient information included.

: Not applicable.

: Kathryn E. Beckermann has received research funding to her institution from Bristol-Myers Squibb and Merck; consulting or advisory roles – Aravive, Bristol-Myers Squibb, Exelixis.Nancy B. Davis has received research funding to her institution from AstraZeneca, Bristol-Myers Squibb, Calithera Biosciences, Hoffman-LaRoche, Immunomedics, Incyte, Jounce Therapeutics, Merck, Mirati Therapeutics, Pfizer, Taris Biomedical; consulting or advisory roles –Janssen.Kerry Schaffer has received research funding to her institution from TEMPUS.Andrew J. Armstrong has received research funding to his institution from AstraZeneca, Bayer, Bristol-Myers Squibb, Constellation Pharmaceuticals, Dendreon, Janssen, Medivation/Astellas, Merck, Novartis, Pfizer, Roche/Genentech, Forma, Amgen; consulting or advisory roles – AstraZeneca, Astellas Scientific, Bayer, Bristol-Myers Squibb, Clovis Oncology, Dendreon, Forma, Merck; Pfizer; other intellectual property – circulating tumor cell novel capture technology.Michael R. Harrison has received research funding to his institution from Acerta, AstraZeneca, Astellas Pharmaceuticals, Bayer, Bristol-Myers Squibb, Clovis Oncology, Exelixis, Genentech, Merck, Pfizer, Seattle Genetics; consulting or advisory roles – AstraZeneca, Bayer, Bristol-Myers Squibb, Exelixis, Fujifilm, Genentech, Janssen Oncology, Pfizer; speaker’s bureau: Exelixis and Genentech.Daniel J. George has received research funding to his institution from Acerta, Astellas Pharmaceuticals, Bayer, Bristol-Myers Squibb, Calithera Biosciences, Dendreon, Exelixis, Janssen, Innocrin Pharma, Novartis, Pfizer, Sanofi/Aventis; consulting or advisory roles – Astellas Pharma, AstraZeneca, Bayer, Bristol-Myers Squibb, Constellation Pharmaceuticals, Exelixis, Genentech, Janssen, Innocrin Pharma, Merck, Michael J Hennessy Associates, Myovant, Physicians Education Resource, Propella Therapeutics, Sanofi, Vizuri; Honoraria – Acceleron Pharma, American Association for Cancer Research, Axess Oncology, Bayer, EMD Serono, Exelixis, Janssen, Millennium Medical Publishing, OncLive, Pfizer, Sanofi, UroToday; Leadership – Capio Biosciences; speaker’s bureau – Bayer, Exelixis, Sanofi.W. Kimryn Rathmell has received research funding to her institution from AstraZeneca, Bristol-Myers Squibb, Calithera Biosciences, Genentech/Roche, Incyte, Peloton Therapeutics, Pfizer, TEMPUS (immediate family member), Kadmon (immediate family member); consulting or advisory roles – Caribou Biosciences and Sitryx; Honoraria – Merck (immediate family member), Pfizer (immediate family member); patents, royalties and other intellectual property – ClearCode34 Risk prediction biomarker for kidney cancer, hERV 3–2 expression as a biomarker of response to immunotherapy; stock and other ownership interests – Caribou Publishing, Sitryx.Brian I. Rini has received research funding to his institution -Aravive, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Dragonfly Therapeutics, Exelixis, Immunomedics, Incyte, Merck, Pfizer, Roche/Genentech, Seattle Genetics, Surface Oncology, Taris; consulting or advisory roles -Aravive, Arrowhead Pharamceuticals, AVEO, Bristol-Myers Squibb, Corvus Pharmaceuticals, Eisai, GlaxoSmithKline, Merck, Pfizer, Surface Oncology, Synthorx, 3D Medicines; Leadership -MJH Life Sciences; Stock and other ownership interests -PTC Therapeutics.Tian Zhang has received research funding to her institution from Acerta Pharma, Astellas Pharma, Janssen, Merrimack, Merck, Mirati Therapeutics, Novartis, OmniSeq, Personal Genome Diagnostics, Pfizer, Regeneron, Stem CentRx; consulting or advisory roles – Amgen, AstraZeneca, Bristol-Myers Squibb, Bristol-Myers Squibb, Calithera Biosciences, Dendreon, Exelixis, Foundation Medicine, Genentech/Roche, Janssen, Pharmacyclics, Pfizer, Sanofi, Seattle Genetics; Honoraria – Exelixis, Genentech/Roche, MJH Life Science, Pacific Genuity; Leadership – Archimmune Therapeutics (immediate family member) and Capio BioSciences (immediate family member); speaker’s bureau – Exelixis, Genentech/Roche, Genomic Health, Sanofi/Aventis; patents, royalties, and other ownership interest – circulating tumor cell novel capture by c-MET technology and prochelators as targeted prodrugs for prostate cancer; stock and other ownership interests – Archimmune Therapeutics (immediate family member), Capio Biosciences (immediate family member), and Nanorobotics (immediate family member).Landon Brown has received consulting fees from Seattle Genetics.The remaining authors report no disclosures.